{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:05Z","timestamp":1790720345278,"version":"4.1.0"},"reference-count":72,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Mycosis fungoides (MF) and S\u00e9zary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T\u2010cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C\u2010C chemokine receptor 4 (CCR4)\u2010directed monoclonal antibody mogamulizumab. Based on the phase\u00a0III pivotal trial, mogamulizumab is recommended by the German S2k\u00a0guidelines for the second\u2010line treatment of stage\u00a0IB and above SS and MF, after at least one prior systemic therapy. Since then, new insights on safety and efficacy of mogamulizumab were generated by post hoc analyses and real\u2010world evidence. A panel of CTCL\u2010experts discussed available literature and own experiences and developed relevant recommendations on the use of mogamulizumab in clinical practice in Germany. The recommendations cover patient criteria, prior therapies, use of mogamulizumab as monotherapy or combination therapy, management of side effects, duration of therapy, and monitoring schedules. The aim of these clinical recommendations is to support healthcare professionals in their decision\u2010making and use of mogamulizumab in daily practice.<\/jats:p>","DOI":"10.1111\/ddg.15639","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T12:25:01Z","timestamp":1735215901000},"page":"341-354","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-9432","authenticated-orcid":false,"given":"Chalid","family":"Assaf","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology Helios Klinikum Krefeld  Krefeld Germany"},{"name":"Institute for Molecular Medicine MSH Medical School Hamburg  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Booken","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4433-2387","authenticated-orcid":false,"given":"Edgar","family":"Dippel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Klinikum Ludwigshafen  Ludwigshafen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7197","authenticated-orcid":false,"given":"Gabor","family":"Dobos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Theodor","family":"Eich","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology M\u00fcnster University Hospital  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus\u2010Detlev","family":"Klemke","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Tumor Center Municipal Hospital Karlsruhe Academic Teaching Hospital of the University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Mitteldorf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology University Medical Center G\u00f6ttingen  G\u00f6ttingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology University Medical Center Mannheim  Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Ludwig\u2010Maximilians\u2010Universit\u00e4t M\u00fcnchen  M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Wobser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology University Hospital W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-6028","authenticated-orcid":false,"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, Allergology and Phlebology Johannes Wesling Clinic University Hospital of the Ruhr University Bochum  Bochum Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00296-9"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06337.x"},{"key":"e_1_2_12_4_1","first-page":"537","article-title":"S2k\u2010Guidelines \u2013 Cutaneous lymphomas (ICD10 C82 \u2010 C86): Update 2021","volume":"20","author":"Dippel E","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202049043"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0402-5"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19669"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26760"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2697"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0983"},{"key":"e_1_2_12_13_1","unstructured":"European Medicines Agency.POTELIGEO\u00ae (mogamulizumab) Summary of Product Characteristics (SmPC) as of May 2024. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/poteligeo\u2010epar\u2010product\u2010information_en.pdf. [Last accessed October 2024]."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17523"},{"key":"e_1_2_12_16_1","unstructured":"Kyowa Kirin Co. Ltd. (2023 September 21). Kyowa Kirin demonstrates commitment to real\u2010world evidence for POTELIGEO\u00ae (mogamulizumab) at EORTC 2023. [Press release]. Available from:https:\/\/international.kyowa\u2010kirin.com\/share\/pdf\/Press_Release_Sept_23\u2010APPROVED\u2010Real\u2010world_evidence_for_POTELIGEO_%28mogamulizumab%29_at_EORTC_2023_%28002%29.pdf[Last accessed October 2024]."},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19134"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102679"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20708"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013341"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0369"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.076"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042203"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100601"},{"key":"e_1_2_12_26_1","article-title":"Fatal acute graft\u2010versus\u2010host disease in S\u00e9zary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation","volume":"72","author":"Trotta GE","year":"2024","journal-title":"Curr Res Transl Med"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19231"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(21)00715-2"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18549"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","unstructured":"StadlerR et\u00a0al.EORTC\u2010CLTG Annual meeting 2024 Lausanne Switzerland 9\u201311th October 2024; Abstract #A\u2010139. B2 involvement as a surrogate marker for a rapid and sustained response to treatment with mogamulizumab in mycosis fungoides and S\u00e9zary syndrome.","DOI":"10.1016\/j.ejca.2024.114378"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12121"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011041"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20588"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3969"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18563"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1953007"},{"key":"e_1_2_12_38_1","unstructured":"ScarisbrickJ ZinzaniP Ortiz\u2010RomeroP et\u00a0al.EORTC\u2010CLTG Congress September 22\u201324th 2022; Madrid Spain; Abstract #TherPO\u201004."},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.8250"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03753-9"},{"key":"e_1_2_12_41_1","article-title":"Abscopal Effect After Localized Radiotherapy in a Patient With S\u00e9zary Syndrome Under Treatment with Mogamulizumab","volume":"13","author":"Grandi V","year":"2023","journal-title":"Dermatol Pract Concept"},{"key":"e_1_2_12_42_1","unstructured":"MorrisS AkilovO GeskinLJ et\u00a0al.European Association of Dermato\u2010Oncology (EADO) virtual October 12\u201314th 2020; poster."},{"key":"e_1_2_12_43_1","unstructured":"AssafC et\u00a0al.EORTC\u2010CLTG Annual meeting 2024 Lausanne Switzerland 9\u201311th October 2024; Abstract #A\u2010200. Mogamulizumab in patients with mycosis fungoides or S\u00e9zary syndrome: Update on the German non\u2010interventional MINT study."},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.11.014"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31090400"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1873530"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14805"},{"key":"e_1_2_12_48_1","first-page":"8118","article-title":"Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T\u2010cell lymphomas: a case series","volume":"26","author":"Teoli M","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13487"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15858"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19457"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010141"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1308491"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03449-7"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21878"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21053"},{"key":"e_1_2_12_58_1","first-page":"992","article-title":"The effect of mogamulizumab on the aberrant T cell population in the peripheral blood \u2010 A monocentric retrospective analysis","volume":"21","author":"Gosmann J","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08363-w"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00624-7"},{"key":"e_1_2_12_61_1","unstructured":"National Cancer Institute (NCI).Common Terminology for Adverse Events (CTCAE) v5.0. Available from:https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html[Last accessed November 21 2023]."},{"key":"e_1_2_12_62_1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/ddg.15432","article-title":"Mogamulizumab\u2010associated rash \u2013 Case series and review of the literature","volume":"22","author":"Hansen I","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0877"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19801"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18741"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.03.022"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i33.4942"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.02.042"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2020.040"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17320"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.06.015"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.10.007"},{"key":"e_1_2_12_73_1","doi-asserted-by":"crossref","unstructured":"StadlerR et\u00a0al.EORTC\u2010CLTG Annual meeting 2024 Lausanne Switzerland 9\u201311th October 2024; oral presentation. RESMAIN: Results of a multicenter randomized double blind placebo\u2010controlled trial to evaluate RESminostat for MAINtenance treatment in advanced stage Mycosis fungoides or S\u00e9zary syndrome.","DOI":"10.1016\/j.ejca.2024.114406"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:52:06Z","timestamp":1741625526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/ddg.15639"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15639","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"2024-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}